Literature DB >> 19918012

Increased carotid intima-media thickness as a predictor of the presence and extent of abnormal myocardial perfusion in type 2 diabetes.

Roxana Djaberi1, Joanne D Schuijf, J Wouter Jukema, Ton J Rabelink, Marcel P Stokkel, Jan W Smit, Eelco J de Koning, Jeroen J Bax.   

Abstract

OBJECTIVE: Identification of asymptomatic patients with type 2 diabetes at increased risk for coronary artery disease (CAD) remains a challenge. We evaluated the potential of carotid intima-media thickness (CIMT) for prediction of abnormal myocardial perfusion in this population. RESEARCH DESIGN AND METHODS: CIMT and SPECT myocardial perfusion imaging were assessed in 98 asymptomatic patients with type 2 diabetes. An increased CIMT was defined as > or =75th percentile of reference values. RESULTS Increased CIMT was an independent predictor of the extent of abnormal perfusion (P < 0.001). In patients with increased CIMT as compared with patients with normal CIMT, abnormal perfusion (75 vs. 9%) and severely abnormal perfusion (28 vs. 3%) were observed more frequently.
CONCLUSIONS: Increased CIMT was significantly related to the presence and extent of abnormal myocardial perfusion. Assessment of CIMT may be useful to identify asymptomatic patients with type 2 diabetes at higher risk for CAD.

Entities:  

Mesh:

Year:  2009        PMID: 19918012      PMCID: PMC2809285          DOI: 10.2337/dc09-1301

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


Identification of asymptomatic patients with type 2 diabetes at increased risk for coronary artery disease (CAD) remains a challenge. In the current study, we evaluated the potential of carotid intima-media thickness (CIMT) to identify asymptomatic patients with type 2 diabetes at higher risk for abnormal myocardial perfusion.

RESEARCH DESIGN AND METHODS

Prospectively, 98 consecutive asymptomatic patients with type 2 diabetes (1) were recruited from a routine outpatient diabetes clinic and referred for cardiovascular risk stratification. Asymptomatic status was confirmed using the Rose questionnaire (2). All patients underwent myocardial perfusion imaging by single-photon emission computed tomography (SPECT) and CIMT assessment.

SPECT data acquisition and data analysis

Myocardial perfusion imaging was performed using electrocardiogram-gated SPECT with 99mTc-sestamibi during pharmacological stress and rest, according to protocols described previously (3). Using a 17-segment model tracer, uptake in each segment was evaluated by two observers in consensus by use of a five-point scoring system (4). The total segmental score during stress was used to determine the extent of abnormal perfusion as reflected by the summed stress score (SSS). Abnormal perfusion was defined as SSS ≥3 and severely abnormal perfusion as SSS ≥8.

CIMT measurement and data analysis

CIMT was assessed using high-resolution B-mode ultrasound with a 10-MHz linear transducer, with an automatic boundary detection system (Art Lab-Esaote-Picus, Genova, Italy). Measurements were performed by an experienced sonographer blinded to clinical information (5). Mean CIMT was assessed throughout 10-mm segments, at four angles, across the far wall of the right and left common carotid artery (CCA). The average of the mean CIMT values of the four segments was calculated to determine the mean right and left CIMT per patient. CIMT values ≥75th percentile (per age and sex category) are defined as increased, indicating elevated cardiovascular risk (5). In the current study, the mean CIMT was compared with reference values from the Multi-Ethnic Study of Atherosclerosis (5). Patients were thereby stratified as having normal CIMT (CIMT <75th percentile) or increased CIMT (CIMT ≥75th percentile in at least one CCA).

Statistical analysis

First, average SSS and standard deviations were calculated in patients with normal or increased CIMT. The independent T test was used to assess the difference in mean SSS between the two groups. Thereafter, univariate analysis of baseline characteristics including age, positive family history of CAD, smoking, hypertension, hypercholesterolemia, BMI, nephropathy (urine albumin/creatinine ≥3.5 mg/mmol), fasting glucose, glycated hemoglobin (by chromatography) (6), retinopathy, peripheral arterial disease, and increased CIMT was performed to identify potential predictors of the extent of abnormal perfusion (SSS). Subsequently, risk factors with a P value <0.05 were included in a linear multiple regression model to identify independent predictors of SSS. Finally, the prevalence of abnormal perfusion (SSS ≥ 3) and severely abnormal perfusion (SSS ≥ 8) was compared between patients with normal and increased CIMT.

RESULTS

Briefly, the mean age of the study population was 54 ± 11 years, with the majority of patients being male (n = 50, 51%). Mean SSS was 3.1 ± 4.2 in the total population. Overall, 34 patients (35%) showed abnormal perfusion (SSS ≥ 3), including severely abnormal perfusion (SSS ≥ 8) in 14 patients (14%). Average CIMT was 0.68 ± 0.12 mm. Comparison with reference values revealed normal CIMT in 60 patients (61%), while in the remaining 38 patients (39%) an increased CIMT value was observed in at least one CCA.

CIMT versus extent of abnormal perfusion

The mean SSS increased significantly from 1.2 ± 2.1 in patients with normal CIMT to 5.6 ± 4.6 in patients with increased CIMT (P < 0.001). Age, smoking, hypertension, nephropathy, and increased CIMT were identified as potential predictors of SSS on SPECT, in a univariate regression model. Importantly, after adjustment for age, smoking, hypertension, and nephropathy in a multivariate model, increased CIMT remained a significant predictor of SSS (P < 0.001) (β = 4.41 [95% CI 3.05–5.76]).

CIMT versus prevalence of abnormal perfusion

Abnormal perfusion was present in 9% of patients with normal CIMT versus 75% of patients with increased CIMT (Fig. 1A). Notably, prevalence of severely abnormal perfusion increased from 3% in patients with normal CIMT to 28% in those with increased CIMT (Fig. 1B).
Figure 1

Relation between CIMT and myocardial perfusion imaging. Prevalence of abnormal perfusion (A) and severely abnormal perfusion (B) was higher in patients with increased CIMT.

Relation between CIMT and myocardial perfusion imaging. Prevalence of abnormal perfusion (A) and severely abnormal perfusion (B) was higher in patients with increased CIMT.

CONCLUSIONS

The prognostic value of SPECT imaging has been confirmed in diabetic patients (7). In particular, a favorable cardiovascular prognosis has been described in patients with normal myocardial perfusion, whereas significantly higher adverse event rates were observed in patients with severely abnormal perfusion (8). SPECT has therefore been proposed as a screening tool for identification of asymptomatic diabetic patients with obstructive CAD (9). However, considering the high global prevalence of type 2 diabetes, a broad screening strategy of all asymptomatic patients using SPECT perfusion imaging does not appear feasible or cost-effective (10). The American Heart Association/American Diabetes Association therefore initially suggested more aggressive medical treatment and assessment of CAD only in the presence of two additional risk factors (9). Nonetheless, baseline analysis of SPECT data in the Detection of Ischemia in Asymptomatic Diabetics Study demonstrated that a selection strategy based on a minimum of two additional risk factors underestimates the presence of abnormal perfusion in a large proportion of patients (41%) (11). Accordingly, the key question remains how asymptomatic diabetic patients with severe CAD should be identified from the general diabetic population. Assessment of CIMT has been previously proposed for this purpose (12). Moreover, the truly noninvasive, inexpensive, and radiation-free nature of CIMT may represent an important advantage over other suggested screening techniques such as coronary calcium scoring (5). However, the relation of CIMT with CAD has not been fully established in asymptomatic diabetic patients. In the current study, increased CIMT was shown to be a strong predictor of the extent of abnormal perfusion and improved identification of patients with severely abnormal perfusion (28%). Normal CIMT values on the other hand were associated with a low risk for abnormal perfusion. Importantly, only few asymptomatic diabetic patients with normal CIMT values had severely abnormal perfusion (3%). However, it must be acknowledged that a nondiabetic control group was not available for comparison. Also, patients were referred from a diabetes clinic and may thus represent a more high-risk group than the general asymptomatic population with diabetes. Nevertheless, our findings suggest that initial risk stratification using CIMT may allow selective referral of asymptomatic patients with type 2 diabetes requiring further imaging and intensification of therapy, thereby improving patient outcome while maintaining cost-effectiveness.
  12 in total

Review 1.  Myocardial perfusion and function: single photon emission computed tomography.

Authors:  Christopher L Hansen; Richard A Goldstein; Olakunle O Akinboboye; Daniel S Berman; Elias H Botvinick; Keith B Churchwell; C David Cooke; James R Corbett; S James Cullom; Seth T Dahlberg; Regina S Druz; Edward P Ficaro; James R Galt; Ravi K Garg; Guido Germano; Gary V Heller; Milena J Henzlova; Mark C Hyun; Lynne L Johnson; April Mann; Benjamin D McCallister; Robert A Quaife; Terrence D Ruddy; Senthil N Sundaram; Raymond Taillefer; R Parker Ward; John J Mahmarian
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

Review 2.  Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.

Authors:  James H Stein; Claudia E Korcarz; R Todd Hurst; Eva Lonn; Christopher B Kendall; Emile R Mohler; Samer S Najjar; Christopher M Rembold; Wendy S Post
Journal:  J Am Soc Echocardiogr       Date:  2008-02       Impact factor: 5.251

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Approved IFCC reference method for the measurement of HbA1c in human blood.

Authors:  Jan-Olof Jeppsson; Uwe Kobold; John Barr; Andreas Finke; Wieland Hoelzel; Tadao Hoshino; Kor Miedema; Andrea Mosca; Pierluigi Mauri; Rita Paroni; Linda Thienpont; Masao Umemoto; Cas Weykamp
Journal:  Clin Chem Lab Med       Date:  2002-01       Impact factor: 3.694

5.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus.

Authors:  X Kang; D S Berman; H C Lewin; I Cohen; J D Friedman; G Germano; R Hachamovitch; L J Shaw
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

6.  Self-administration of a questionnaire on chest pain and intermittent claudication.

Authors:  G Rose; P McCartney; D D Reid
Journal:  Br J Prev Soc Med       Date:  1977-03

7.  Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study.

Authors:  Paul Valensi; Jacques Pariès; Valérie Brulport-Cerisier; Florence Torremocha; Régis-Nessim Sachs; Gérald Vanzetto; Emmanuel Cosson; Boris Lormeau; Jean-Raymond Attali; Richard Maréchaud; Bruno Estour; Serge Halimi
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

Review 8.  Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management.

Authors:  Paolo Raggi; Antonio Bellasi; Carlo Ratti
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

9.  Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.

Authors:  Frans J Th Wackers; Lawrence H Young; Silvio E Inzucchi; Deborah A Chyun; Janice A Davey; Eugene J Barrett; Raymond Taillefer; Steven D Wittlin; Gary V Heller; Neil Filipchuk; Samuel Engel; Robert E Ratner; Ami E Iskandrian
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

10.  Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.

Authors:  Lawrence H Young; Frans J Th Wackers; Deborah A Chyun; Janice A Davey; Eugene J Barrett; Raymond Taillefer; Gary V Heller; Ami E Iskandrian; Steven D Wittlin; Neil Filipchuk; Robert E Ratner; Silvio E Inzucchi
Journal:  JAMA       Date:  2009-04-15       Impact factor: 56.272

View more
  4 in total

1.  Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.

Authors:  Atsushi Tanaka; Atsushi Kawaguchi; Jun-Ichi Oyama; Tomoko Ishizu; Hiroshi Ito; Jun Fukui; Taizo Kondo; Shigetaka Kuroki; Mamoru Nanasato; Yukihito Higashi; Kohei Kaku; Teruo Inoue; Toyoaki Murohara; Koichi Node
Journal:  Heart Vessels       Date:  2018-10-03       Impact factor: 2.037

2.  Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home
Journal:  Diabetes Metab Syndr Obes       Date:  2011-01-19       Impact factor: 3.168

3.  The association of carotid intima media thickness with retinol binding protein-4 and total and high molecular weight adiponectin in type 2 diabetic patients.

Authors:  Masoumeh Mansouri; Ramin Heshmat; Ozra Tabatabaei-Malazy; Farshad Sharifi; Zohreh Badamchizadeh; Sudabeh Alatab; Kobra Omidfar; Hossein Fakhrzadeh; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2012-08-02

Review 4.  Carotid intima-media thickness: Current evidence, practices, and Indian experience.

Authors:  Ravi R Kasliwal; Manish Bansal; Devang Desai; Maya Sharma
Journal:  Indian J Endocrinol Metab       Date:  2014-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.